ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 195 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 2.98 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $637,231 | -91.5% | 13,698 | -92.3% | 0.00% | -93.9% |
| Q4 2020 | $7,464,000 | -30.3% | 177,288 | -24.2% | 0.03% | -21.4% |
| Q3 2020 | $10,704,000 | +25.2% | 233,820 | +37.3% | 0.04% | -2.3% |
| Q2 2020 | $8,551,000 | -15.4% | 170,324 | -13.4% | 0.04% | -34.8% |
| Q1 2020 | $10,111,000 | -45.5% | 196,605 | -34.5% | 0.07% | +8.2% |
| Q4 2019 | $18,540,000 | +4.3% | 300,085 | +1.4% | 0.06% | -7.6% |
| Q3 2019 | $17,781,000 | +100.3% | 295,954 | +181.3% | 0.07% | +106.2% |
| Q2 2019 | $8,878,000 | +30.7% | 105,211 | +48.0% | 0.03% | +23.1% |
| Q1 2019 | $6,792,000 | +198.8% | 71,111 | +121.6% | 0.03% | +160.0% |
| Q4 2018 | $2,273,000 | -61.1% | 32,088 | -53.1% | 0.01% | -52.4% |
| Q3 2018 | $5,847,000 | -60.7% | 68,417 | -46.7% | 0.02% | -65.6% |
| Q2 2018 | $14,872,000 | -33.3% | 128,317 | -53.5% | 0.06% | -40.2% |
| Q1 2018 | $22,310,000 | – | 275,742 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
| Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
| Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
| Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
| Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
| ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
| Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
| Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |